BTCY
Biotricity, Inc.0.3799
+0.0399+11.7%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q3 '26
No Q&A; reaffirms outlook
No analyst questions emerged, leaving Biotricity's prepared remarks unchallenged and Q&A entirely absent. Closing comments simply echoed the script's optimism, reiterating top-line growth and a shift to net income positive in 2026 without fresh details or nuance. No pushback on execution risks or competitive dynamics. Q&A added nothing new. Investors watch for actual profitability delivery next quarter.
Key Stats
Market Cap
10.62MP/E (TTM)
-Basic EPS (TTM)
-0.14Dividend Yield
0%Recent Filings
8-K
Q3 revenue hits $4M
Biotricity reported Q3 fiscal 2026 revenue up 10.2% to $4 million, with gross margin expanding to 81.5% from 76.4% and net loss shrinking 13% to $1.1 million. Recurring TaaS fees surged 7.4% to $3.6 million, or 91.2% of revenue, fueled by AI efficiencies and cardiac monitoring adoption. App users scaled to 44,000. FDA clearance for Cardiac AI Cloud looms.
10-Q
Q3 FY2026 results
Biotricity posted Q3 FY2026 revenue of $3.99M, up 10.2% y/y from $3.62M, with technology fees at $3.64M (91% of total) driving gains alongside device sales. Gross margin hit 81.5%, up from 76.4%, while operating profit swung to $441K from a $169K loss—third straight positive quarter. Cash fell to $256K amid $14.5B debt load, yet operating cash use improved sharply. Revenue grows. Balance sheet strains.
8-K
Revenue up 19%, margins expand
10-Q
Q2 FY2026 results
Biotricity posted Q2 FY2026 revenue of $3.9M, up 19% y/y from $3.3M, with technology fees at $3.5M (90% of total) driving gains alongside device sales; gross margin hit 81.9%, up from 75.3%. Operating profit swung to $274K from a $308K loss, thanks to steady SG&A while R&D ticked higher on ecosystem builds. Cash fell to $308K amid $42K operating inflow (six-month positive), yet term loan ($14.4M total) and convertibles ($10.4M) pile pressure—net loss trailed operating by interest and accretion. Revenue grows. Debt weighs heavy.
10-Q
Q1 FY2026 results
Biotricity swung to its first operating profit of $281,945 for Q1 FY2026 ended June 30, 2025, fueled by revenue up 21% y/y to $3.9M (technology fees +12% y/y to $3.4M, devices +171% y/y to $503K) while gross margin expanded 6.7 points to 80.5%. SG&A fell 28% y/y to $2.1M yet R&D rose 35% y/y to $696K on ecosystem enhancements; net loss narrowed to $672K before $82K preferred dividends, mainly from $850K interest. Cash ticked to $391K with $436K financing inflows offsetting $373K operating use, atop $14.8M term loan (due 2026) and $10.1M convertibles. Debt burden looms large.
BBNX
Beta Bionics, Inc.
29.63-0.09
BFLY
Butterfly Network, Inc.
3.34+0.12
BIO
Bio-Rad Laboratories, Inc.
302.02-5.90
BSX
Boston Scientific Corporation
92.95+0.76
CVRX
CVRx, Inc.
8.32+0.14
DXCM
DexCom, Inc.
66.37+0.64
GCTK
GlucoTrack, Inc.
5.18+0.03
IRTC
iRhythm Technologies, Inc.
167.90-1.10
MASI
Masimo Corporation
134.52-2.88
NMTC
NeuroOne Medical Technologies C
0.71+0.05